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PreviewsMaking a New Turn In Matrix
Metalloprotease Inhibition
The paradigm for matrix metalloprotease inhibition
combines active site tailoring and catalytic zinc liga-
tion. But, selectivity has been difficult. Now, Engel et
al. [1] present novel compounds, completely selective
for MMP-13, with a unique binding mode.
The enzymes that cleave collagen, gelatin, and other
proteins of the extracellular matrix belong to the family
of multidomain, zinc-dependent proteins known as ma-
trix metalloproteases (MMPs) [2]. Although the number
and nature of subunits can differ, each enzyme contains
a homologous catalytic domain with the active site sig-
nature sequence HExxHxxGxxH. For 11 members of
the family, the catalytic domain crystal structure has
been determined.
Involved not only in normal tissue remodeling, but
also in diseases such as cancer, arthritis, and periodon-
tal disease, MMPs have become popular targets for
drug design. But, to date, no inhibitor of an MMP cata-
lytic domain has become a drug. One major problem
seems to be selectivity; although preferred substrates
for the various members of the family differ, in some
cases substrate specificity has been shown to be de-
pendent on domains other than the catalytic one [3].
Since the catalytic domain itself can thus be promiscu-
ous, severe difficulties arise when designing selective
small-molecule inhibitors.
With sequence identity of 50%–60%, MMP catalytic
domain structures are highly similar. The basic topology
consists of a 5-stranded, curved β sheet and three α
helices, all on the concave side of the sheet. The first
two histidine residues of the signature sequence pro-
trude from adjacent turns of the catalytic helix, which
extends across the rear of the active site. The con-
served glycine induces a turn, necessary to bring the
third histidine in proximity to the other two; all three
coordinate the catalytic zinc ion. A methionine, con-
served in MMPs and also in members of structurally
related families, forms a Met turn directly beneath the
zinc, providing the name metzincin to the set of fam-
ilies.
MMPs are expressed with a propeptide of about 80
residues just N-terminal to the catalytic domain. Initially
inactive because a prodomain cystine coordinates the
zinc, activation occurs when the prodomain is removed
by proteolytic cleavage. The mechanism of replacing
the cystine with bound water has been denoted the
“cystine switch.”
The catalytic mechanism is considered to be the
same as that of thermolysin [4], involving the zinc ion,
the signature glutamic acid, and a zinc bound water
molecule. Substrates bind in a groove extending across
the face of the protein. Shallow on the unprimed side,it deepens to an extended pocket on the far side of the
zinc at S1#; however, beyond S1#, it is again relatively
flat. Effective inhibitors have achieved tight binding via
extensive van der Waals contacts within the largely hy-
drophobic interior of S1# and by strong electrostatic in-
teractions with zinc.
But, compounds selective for a single MMP family
member have been hard to achieve [5]. The active sites
of MMPs are both homologous and structurally very
similar, as is the entrance to S1#. Apart from MMP-1,
-7, and -11 (in which pockets are occluded by arginine,
tyrosine, or glutamine side chains, respectively), S1#s
are long and straight, longer than any naturally occur-
ring amino acid, and may even form a tunnel through
the protein core (Figure 1). Although there are differ-
ences of both composition and length in the segment
on the exterior wall of S1#, denoted the “specificity
loop,” that part of the protein has been shown to be
quite flexible. The conformation of amino acid side
chains can vary depending on the nature of the inhibitor
with which the protein is crystallized [5, 6]. More dra-
matic structural changes were found in a complex of
MMP-3 with an unprimed side inhibitor, where atoms of
the backbone were shifted up to 4 Å from their usual
positions, presumably because the pocket was unoc-
cupied [7]. In a few MMP structures, several residues
of the loop are disordered [1]. Evidently, the pockets
can adapt to accommodate diverse ligands. While S3,
S2, S1, S2#, and S3# sites are not as similar, they are
either shallow or solvent exposed, and opportunities
for tight binding are limited.
The problem is compounded by the more recently
discovered ADAM (a disintegrin and metalloprotease)
family [8], also metzincins and of similar topology.
These membrane bound enzymes act as sheddases,
liberating membrane bound cytokines, cell surface re-
ceptors, and growth factors as physiologically active
soluble proteins [9]. For some of them, substrates have
not yet been identified. The catalytic sites of ADAM
family members also manifest the MMP signature se-
quence HExxHxxGxxH, and small molecules that inhibit
MMPs frequently also inhibit ADAM family members.
It has even been suggested that musculoskeletal pain
associated with broad-spectrum MMP inhibitors may
be due to simultaneous inhibition of ADAM proteins
[10]. This makes selectivity within and between the
families even more important. As expected, the two
known structures of ADAM proteins [11, 12] have active
sites very similar to those of the MMPs. They are mutu-
ally alike, although there are some differences in the
distal ends of the S1# pockets. It will be interesting to
evaluate similarity within this family when additional
structures have been determined.
Since the first attempts at MMP inhibition, hy-
droxamic acid has been the preferred zinc-chelating
group [5]. Its binding orientation allows linkage to a di-
verse family of scaffolds, each of which projects P1#
directly into S1#. The geometry is ideal because polar
atoms interact simultaneously with zinc, the side chain
of the catalytic Glu, and the backbone of a strand lying
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WFigure 1. Cross-Sections through the S1# Pockets of Four Superim-
posed MMP Crystal Structures
The inhibitor (green) was cocrystallized with MMP-3 but could also
fit the other three. The proteins are stromelysin-1 (MMP-3, pink), S
gelatinase A (MMP-2, beige), collagenase-3 (MMP-13, yellow), and
macrophage elastase (MMP-12, cyan).just above the catalytic site. It has recently been pro-
posed to bind in its neutral form, providing protons for
the hydrogen bonds [13]. Carboxylic acid, on the other
hand, supposedly binds in a charged form and also has
a less favorable geometry; when used in inhibitors, it
decreases the affinity 1–2 orders of magnitude. Hy-
droxamic acids, though, have been associated with
metabolic instability [14].
Hydroxamate replacements such as thiols, phospho-
nates, thiadiazoles, thiadiazines, barbituric acids, and
hydantoins have been investigated [15]. For the most
part, these suffer from weaker affinity, reduced absorption
rates, or toxicity; some are too recent for their potential
to have been fully explored. The search for improved, 1
novel zinc binding groups is a continuous one [16].
1On page 181 of this issue, Engel et al. [1] present a
series of MMP-13 inhibitors that overcome the issues
of both selectivity and zinc chelation by binding deep
within the S1# pocket and an additional small region 1
denoted the “S1# side pocket.” The concept is not new;
there is probably no group working in the field that has
1not, at some time, considered the possibility of nonche-
lating compounds. There are even a few examples in 1
the literature. A weak inhibitor of MMP-13 was found,
1by NMR, to bind within S1# well beyond the zinc ion,
but it was only after linkage to hydroxamic acid that
reasonable affinity was achieved [17]. More recent are
crystal structures of nonchelating inhibitors of MMP-12 1
[18] in a ternary complex with acetohydroxamate (AH),
1which had been added to improve solubility and is
bound to zinc. The presence of AH also improved affin-
ity dramatically, for reasons that are not completely 1
understood.
In the current work [1], a crystal structure with thenitial compound indicated its novel binding mode. At
ts midpoint, the molecule, which appears to be almost
ompletely buried, makes a turn from S1# into the S1#
ide pocket. In this conformation, it embraces a leucyl
ide chain “like gripping pliers.” Rational design then
ffected improvement to single-digit nanomolar affinity.
o inhibition of any other MMP was detected. To our
nowledge, these are the first selective, nonchelating
nhibitors of high affinity reported.
The authors argue convincingly that complete MMP-
3 specificity of these compounds is due to the length
nd amino acid composition of the inhibitor binding se-
ectivity loop. The interesting question is whether MMP-
3 is unique, as the authors suggest, or whether this is
he first of a sequence of finely tuned MMP and ADAM
nhibitors, each specific to a single enzyme. Develop-
ents in this field bear careful watching.
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